Skip to Content
Return to Search

USE OF GLYCOLYTIC PATHWAYS FOR INHIBITING OR MEASURING ONCOGENIC SIGNALING

United States Patent Application

*** PATENT GRANTED ***
20140073523
9,689,042
A1
View the Complete Application at the US Patent & Trademark Office
Lawrence Berkeley National Laboratory - Visit the Technology Transfer and Intellectual Property Management Department Website
Disclosed are methods in which glucose metabolism is correlated to oncogenesis through certain specific pathways; inhibition of certain enzymes is shown to interfere with oncogenic signaling, and measurement of certain enzyme levels is correlated with patient survival. The present methods comprise measuring level of expression of at least one of the enzymes involved in glucose uptake or metabolism, wherein increased expression of the at least one of the enzymes relative to expression in a normal cell correlates with poor prognosis of disease in a patient. Preferably the genes whose expression level is measured include GLUT3, PFKP, GAPDH, ALDOC, LDHA and GFPT2. Also disclosed are embodiments directed towards down-regulating the expression of some genes in glucose uptake and metabolism.
Onodera, Yasuhito (Sapporo, JP), Bissell, Mina (Berkeley, CA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland CA)
14/ 020,361
September 6, 2013
STATEMENT OF GOVERNMENTAL SUPPORT [0002] This invention was made with U.S. Government support under Contract Number DE-AC02-05CH11231 between the U.S. Department of Energy and The Regents of the University of California for the management and operation of the Lawrence Berkeley National Laboratory. The U.S. Government has certain rights in this invention.